Overexpression of the pp32r1 (ANP32C) oncogene or its functional mutant pp32r1Y140H confers enhanced resistance to FTY720 (Finguimod)

Cancer Biology and Therapy

Volumn 15, Issue 3, 2014, Pages 289-296

  Buddaseth, Salma ^a   Göttmann, Wiebke ^a   Blasczyk, Rainer ^a   Huyton, Trevor ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cancer; Cell cycle; FTY720; Pp32

Indexed keywords

FINGOLIMOD; HUR PROTEIN; MESSENGER RNA; PP32 PROTEIN; PP32R1 PROTEIN; PROTEIN PHOSPHATISE 2A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ANP32C PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; NUCLEAR PROTEIN; PHOSPHOPROTEIN; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL VIABILITY; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; UTERINE CERVIX CANCER; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; LENTIVIRINAE; METABOLISM; MOLECULAR DOCKING; MUTATION; ONCOGENE; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENETIC VECTORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LENTIVIRUS; MOLECULAR DOCKING SIMULATION; MUTATION; NUCLEAR PROTEINS; ONCOGENES; PHOSPHOPROTEINS; PROPYLENE GLYCOLS; PROTEIN STRUCTURE, TERTIARY; REPETITIVE SEQUENCES, AMINO ACID; SPHINGOSINE; TRANSDUCTION, GENETIC;

EID: 84896528301     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.27307     Document Type: Article

References (41)

1. Matilla A, Radrizzani M. The Anp32 family of proteins containing leucine-rich repeats. Cerebellum 2005; 4:7-18; PMID:15895553; http://dx.doi.org/10.1080/14734220410019020 (Pubitemid 40592803)
2. Malek SN, Katumuluwa AI, Pasternack GR. Identification and preliminary characterization of two related proliferation-associated nuclear phosphoproteins. J Biol Chem 1990; 265:13400-9; PMID:2376600 (Pubitemid 20234300)
3. Matilla A, Koshy BT, Cummings CJ, Isobe T, Orr HT, Zoghbi HY. The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. Nature 1997; 389:974-8; PMID:9353121; http://dx.doi.org/10.1038/40159 (Pubitemid 27485689)
4. Opal P, Garcia JJ, McCall AE, Xu B, Weeber EJ, Sweatt JD, Orr HT, Zoghbi HY. Generation and characterization of LANP/pp32 null mice. Mol Cell Biol 2004; 24:3140-9; PMID:15060138; http://dx.doi.org/10.1128/MCB.24.8.3140-3149.2004 (Pubitemid 38452060)
5. Reilly PT, Afzal S, Gorrini C, Lui K, Bukhman YV, Wakeham A, Haight J, Ling TW, Cheung CC, Elia AJ, et al. Acidic nuclear phosphoprotein 32kDa (ANP32)B-deficient mouse reveals a hierarchy of ANP32 importance in mammalian development. Proc Natl Acad Sci U S A 2011; 108:10243-8; PMID:21636789; http://dx.doi.org/10.1073/pnas.1106211108
6. Reilly PT, Afzal S, Wakeham A, Haight J, You-Ten A, Zaugg K, Dembowy J, Young A, Mak TW. Generation and characterization of the Anp32e-deficient mouse. PLoS One 2010; 5:e13597; PMID:21049064; http://dx.doi.org/10.1371/journal.pone. 0013597
7. Brody JR, Kadkol SS, Mahmoud MA, Rebel JM, Pasternack GR. Identification of sequences required for inhibition of oncogene-mediated transformation by pp32. J Biol Chem 1999; 274:20053-5; PMID:10400610; http://dx.doi.org/10.1074/ jbc.274.29.20053
8. Kadkol SS, Brody JR, Pevsner J, Bai J, Pasternack GR. Correction to "Modulation of oncogenic potential by alternative gene use in human prostate cancer". Nat Med 1999; 5:1087; PMID:10471270; http://dx.doi.org/ 10.1038/12530 (Pubitemid 29439585)
9. Adegbola O, Pasternack GR. Phosphorylated retinoblastoma protein complexes with pp32 and inhibits pp32-mediated apoptosis. J Biol Chem 2005; 280:15497-502; PMID:15716273; http://dx.doi.org/10.1074/jbc.M411382200 (Pubitemid 40616664)
10. Kobe B, Kajava AV. The leucine-rich repeat as a protein recognition motif. Curr Opin Struct Biol 2001; 11:725-32; PMID:11751054; http://dx.doi.org/10.1016/S0959-440X(01)00266-4 (Pubitemid 34076634)
11. Huyton T, Wolberger C. The crystal structure of the tumor suppressor protein pp32 (Anp32a): structural insights into Anp32 family of proteins. Protein Sci 2007; 16:1308-15; PMID:17567741; http://dx.doi.org/10.1110/ps. 072803507 (Pubitemid 46984865)
12. Chen TH, Brody JR, Romantsev FE, Yu JG, Kayler AE, Voneiff E, Kuhajda FP, Pasternack GR. Structure of pp32, an acidic nuclear protein which inhibits oncogene-induced formation of transformed foci. Mol Biol Cell 1996; 7:2045-56; PMID:8970164; http://dx.doi.org/10.1091/mbc.7.12.2045 (Pubitemid 26415009)
13. Brennan CM, Gallouzi IE, Steitz JA. Protein ligands to HuR modulate its interaction with target mRNAs in vivo. J Cell Biol 2000; 151:1-14; PMID:11018049; http://dx.doi.org/10.1083/jcb.151.1.1
14. Buddaseth S, Göttmann W, Blasczyk R, Huyton T. Dysregulation of cell cycle control caused by overexpression of the oncogene pp32r1 (ANP32C) and the Tyr>His mutant pp32r1Y140H. Biochim Biophys Acta 2013; 1833:1212-21; PMID:23403278; http://dx.doi.org/10.1016/j.bbamcr.2013.02.001
15. Kochevar GJ, Brody JR, Kadkol SS, Murphy KM, Pasternack GR. Identification of a functional mutation in pp32r1 (ANP32C). Hum Mutat 2004; 23:546-51; PMID:15146458; http://dx.doi.org/10.1002/humu.20030 (Pubitemid 38720605)
16. Habrukowich C, Han DK, Le A, Rezaul K, Pan W, Ghosh M, Li Z, Dodge-Kafka K, Jiang X, Bittman R, et al. Sphingosine interaction with acidic leucinerich nuclear phosphoprotein-32A (ANP32A) regulates PP2A activity and cyclooxygenase (COX)-2 expression in human endothelial cells. J Biol Chem 2010; 285:26825-31; PMID:20558741; http://dx.doi.org/10.1074/jbc.M110.147058
17. Tedesco-Silva H, Mourad G, Kahan BD, Boira JG, Weimar W, Mulgaonkar S, Nashan B, Madsen S, Charpentier B, Pellet P, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2004; 77:1826-33; PMID:15223899 (Pubitemid 38822204)
18. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW; FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355:1124-40; PMID:16971719; http://dx.doi.org/10.1056/NEJMoa052643 (Pubitemid 44394919)
19. Shen Y, Cai M, Xia W, Liu J, Zhang Q, Xie H, Wang C, Wang X, Zheng S. FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells. Cancer Lett 2007; 254:288-97; PMID:17462818; http://dx.doi.org/10.1016/j.canlet.2007.03.013 (Pubitemid 47161105)
20. Azuma H, Takahara S, Horie S, Muto S, Otsuki Y, Katsuoka Y. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol 2003; 169:2372-7; PMID:12771800; http://dx.doi.org/10.1097/01. ju.0000064938.32318.91 (Pubitemid 36576803)
21. Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, Lehman A, Perrotti D, Chen CS, Dalton JT, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 2008; 111:275-84; PMID:17761520; http://dx.doi.org/10.1182/blood-2006-10- 053884
22. Liao A, Broeg K, Fox T, Tan SF, Watters R, Shah MV, Zhang LQ, Li Y, Ryland L, Yang J, et al. Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood 2011; 118:2793-800; PMID:21768294; http://dx.doi.org/10. 1182/blood-2011-01-331447
23. Chua CW, Lee DT, Ling MT, Zhou C, Man K, Ho J, Chan FL, Wang X, Wong YC. FTY720, a fungus metabolite, inhibits in vivo growth of androgenindependent prostate cancer. Int J Cancer 2005; 117:1039-48; PMID:15986440; http://dx.doi.org/10.1002/ijc.21243 (Pubitemid 41688582)
24. Ho JW, Man K, Sun CK, Lee TK, Poon RT, Fan ST. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol Cancer Ther 2005; 4:1430-8; PMID:16170036; http://dx.doi.org/10.1158/1535-7163.MCT-05-0021
25. Lee TK, Man K, Ho JW, Sun CK, Ng KT, Wang XH, Wong YC, Ng IO, Xu R, Fan ST. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis 2004; 25:2397-405; PMID:15297371; http://dx.doi.org/10.1093/carcin/bgh250 (Pubitemid 39625180)
26. Permpongkosol S, Wang JD, Takahara S, Matsumiya K, Nonomura N, Nishimura K, Tsujimura A, Kongkanand A, Okuyama A. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cellcycle entry and apoptosis. Int J Cancer 2002; 98:167-72; PMID:11857403; http://dx.doi.org/10.1002/ijc.10178 (Pubitemid 34150797)
27. Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M, Brody JR. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res 2009; 69:4567-72; PMID:19487279; http://dx.doi.org/10.1158/0008-5472.CAN-09-0371
28. Williams TK, Costantino CL, Bildzukewicz NA, Richards NG, Rittenhouse DW, Einstein L, Cozzitorto JA, Keen JC, Dasgupta A, Gorospe M, et al. pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs. PLoS One 2010; 5:e15455; PMID:21152064; http://dx.doi.org/10.1371/journal.pone.0015455
29. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. Auto Dock4 and Auto Dock Tools4: Automated docking with selective receptor flexibility. J Comput Chem 2009; 30:2785-91; PMID:19399780; http://dx.doi.org/ 10.1002/jcc.21256
30. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007; 117:2408-21; PMID:17717597; http://dx.doi.org/10.1172/JCI31095 (Pubitemid 47494343)
31. Don AS, Martinez-Lamenca C, Webb WR, Proia RL, Roberts E, Rosen H. Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues. J Biol Chem 2007; 282:15833-42; PMID:17400555; http://dx.doi.org/10.1074/jbc.M609124200 (Pubitemid 47093290)
32. Wallington-Beddoe CT, Hewson J, Bradstock KF, Bendall LJ. FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells. Autophagy 2011; 7:707-15; PMID:21460633; http://dx.doi.org/10.4161/auto.7.7.15154
33. Seo SB, Macfarlan T, McNamara P, Hong R, Mukai Y, Heo S, Chakravarti D. Regulation of histone acetylation and transcription by nuclear protein pp32, a subunit of the INHAT complex. J Biol Chem 2002; 277:14005-10; PMID:11830591; http://dx.doi.org/10.1074/jbc.M112455200 (Pubitemid 34968009)
34. Chakravarti D, Hong R. SET-ting the stage for life and death. Cell 2003; 112:589-91; PMID:12628178; http://dx.doi.org/10.1016/S0092-8674(03)00151-X (Pubitemid 36335801)
35. Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam SP, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2ARIPK1-dependent necroptosis. EMBO Mol Med 2013; 5:105-21; PMID:23180565; http://dx.doi.org/10.1002/emmm.201201283
36. Li M, Damuni Z. I1PP2A and I2PP2A. Two potent protein phosphatase 2A-specific inhibitor proteins. Methods Mol Biol 1998; 93:59-66; PMID:9664527
37. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 2004; 6:308-18; PMID:15048125; http://dx.doi.org/10.1038/ncb1110 (Pubitemid 38584820)
38. Kadkol SS, Brody JR, Pevsner J, Bai J, Pasternack GR. Modulation of oncogenic potential by alternative gene use in human prostate cancer. Nat Med 1999; 5:275-9; PMID:10086381; http://dx.doi.org/10.1038/12530 (Pubitemid 29124361)
39. Kadkol SS, El Naga GA, Brody JR, Bai J, Gusev Y, Dooley WC, Pasternack GR. Expression of pp32 gene family members in breast cancer. Breast Cancer Res Treat 2001; 68:65-73; PMID:11678310; http://dx.doi.org/10.1023/A:1017919507109 (Pubitemid 32928272)
40. Wang JD, Takahara S, Nonomura N, Ichimaru N, Toki K, Azuma H, Matsumiya K, Okuyama A, Suzuki S. Early induction of apoptosis in androgenindependent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate 1999; 40:50-5; PMID:10344723; http://dx.doi.org/10.1002/(SICI)1097- 0045(19990615)40:1<50::AIDPROS6>3.0.CO;2-N (Pubitemid 29244494)
41. Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, Salunkhe V, Teissié J, Malavaud B, Waxman J, et al. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res 2010; 70:8651-61; PMID:20959468; http://dx.doi.org/10.1158/ 0008-5472.CAN-10-1388